Activist Investor Juniper Increases Stake in Orthofix Medical to 9.6% with $7.9M in Open Market Purchases
OFIX sits 31% above its 52-week low of $10.24.
Summary
Activist investor Juniper Investment Company has increased its beneficial ownership in Orthofix Medical to 9.6% through recent open market purchases totaling $7.9 million.
Key Events · Ownership and Investor Activity · OFIX
-
Increased Beneficial Ownership
Juniper Investment Company and its affiliates now beneficially own 3,784,617 shares, representing approximately 9.6% of Orthofix Medical's outstanding common stock.
-
Significant Open Market Purchases
Between October 20, 2025, and February 12, 2026, Juniper Targeted Opportunity Fund, L.P. purchased 541,333 shares for approximately $7,916,857 in the open market.
-
Activist Investor Position
This filing is an amendment to a Schedule 13D, indicating an activist stance and potential for future strategic involvement by Juniper Investment Company.
Analysis · OFIX · Industrial Applications And Services
Juniper Investment Company, an activist investor, has significantly increased its stake in Orthofix Medical, accumulating an additional $7.9 million worth of shares. This substantial investment, bringing their total ownership to 9.6%, signals strong conviction in the company's value and could precede further engagement or demands for strategic changes. Investors should monitor Juniper's future actions and communications for potential catalysts.
How filings like this one have moved
In the 30 days to Sep 21, 2026, 34.9% of the 999 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OFIX was trading at $13.38 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $529.8M. The 52-week trading range was $10.24 to $20.48. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.